6α-chloropenicillanic acid 1,1-dioxide | 76350-36-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 6α-chloropenicillanic acid 1,1-dioxide
• 英文别名: 6-alpha-chloropenicillanic acid 1,1-dioxide；Penicillin Impurity 3；(2S,5R,6S)-6-chloro-3,3-dimethyl-4,4,7-trioxo-4λ6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
• CAS: 76350-36-2
• 化学式: C₈H₁₀ClNO₅S
• 分子量: 267.69
• InChiKey: FDCNRFPOQKKBGS-RVJQKOHUSA-N

物化性质

• 沸点：
  599.6±50.0 °C(Predicted)
• 密度：
  1.72±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  100
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  6α-chloropenicillanic acid 1,1-dioxide 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 苯 为溶剂， 反应 1.0h， 以91%的产率得到6α-chloro-3α-chlorocarbonyl-2,2-dimethylpenam S,S-dioxide
  参考文献：
  名称：

  Mata, Ernesto G.; Boschetti, Carlos E.; Mascaretti, Oreste A., Organic Preparations and Procedures International, 1995, vol. 27, # 2, p. 229 - 232

  摘要：

  DOI：
• 作为产物：
  描述：

  6-chloropenicillanic acid 在 potassium fluoride 、 三氯化铝 、 间氯过氧苯甲酸 、 Merrifield resin 作用下， 生成 6α-chloropenicillanic acid 1,1-dioxide
  参考文献：
  名称：

  固体支持物上的β-内酰胺：使用氯化铝温和有效地去除Merrifield树脂中的青霉素衍生物

  摘要：

  在二氯甲烷/硝基甲烷中使用氯化铝，在温和条件下，可以有效地将与Merrifield树脂连接的青霉素衍生物从该载体中释放出来。还报道了王树脂连接类似物的扩展以及对青霉素固相氧化的研究。©1997爱思唯尔科学有限公司。

  DOI：

  10.1016/s0040-4039(97)01457-3

文献信息

• Intermediates for production of 1,1-dioxopenicillanoyloxymethyl
  申请人：Pfizer Inc.

  公开号：US04393001A1

  公开（公告）日：1983-07-12

  Compounds of the formula ##STR1## wherein R.sup.1 is H or HO; Y and Z are each Cl, Br or I, or Y is H and Z is Cl, Br or I; Q is N.sub.3 or NHCO.sub.2 CH.sub.2 C.sub.6 H.sub.4 R.sup.4 where R.sup.4 is H, Cl, Br, NO.sub.2, CH.sub.3 or OCH.sub.3 ; a process for their use in production of the valuable antibacterial agents 1,1-dioxopenicillanoyloxymethyl 6-(2-amino-2-phenylacetamido)penicillanate and 1,1-dioxopenicillanoyloxymethyl 6-[2-amino-2-(p-hydroxyphenyl)acetamido]-penicillanate, by catalytic hydrogenation in the presence of a noble metal catalyst and novel intermediates useful in preparing said compounds of formula (I).

  式##STR1##中的化合物，其中R.sup.1为H或HO；Y和Z分别为Cl、Br或I，或者Y为H且Z为Cl、Br或I；Q为N.sub.3或NHCO.sub.2 CH.sub.2 C.sub.6 H.sub.4 R.sup.4，其中R.sup.4为H、Cl、Br、NO.sub.2、CH.sub.3或OCH.sub.3；它们在生产有价值的抗菌剂1,1-二氧代青霉烷酰氧甲基6-(2-氨基-2-苯乙酰氨基)青霉烷酸酯和1,1-二氧代青霉烷酰氧甲基6-[2-氨基-2-(对羟基苯基)乙酰氨基]-青霉烷酸酯的用途中的过程，通过在贵金属催化剂存在下的催化氢化，以及在制备式(I)化合物中有用的新型中间体。
• Preparation of halomethyl esters (and related esters) of penicillanic
  申请人：Pfizer Inc.

  公开号：US04419284A1

  公开（公告）日：1983-12-06

  Process for preparation of halomethyl esters (and related esters) of penicillanic acid 1,1-dioxide of the formula ##STR1## where X is Cl, Br, I, certain alkylsulfonyloxy or arylsulfonyloxy groups, useful as intermediates in production of antibiotics having beta-lactamase activity, which comprises hydrogenolysis of an ester of the formula ##STR2## where n is zero, 1 or 2; Y and Z are each Cl, Br or I, or Y is H and Z is Cl, Br, I, C.tbd.N-- or SCN--, or Y is arylselenyl and Z is Cl or Br; and when n is zero or 1, oxidation of the hydrogenolysis product; a process for preparing compounds of formula (VI, n=2) by oxidation of the corresponding compound (VI) wherein n is zero or 1, and certain novel intermediates useful in the above processes.

  制备青霉素酸1,1-二氧化物的卤甲酯（和相关酯）的过程的公式为##STR1##其中X为Cl、Br、I、某些烷基磺酰氧或芳基磺酰氧基团，用作生产具有β-内酰胺酶活性的抗生素的中间体，包括以下步骤：对公式为##STR2##的酯进行氢解反应，其中n为零、1或2；Y和Z分别为Cl、Br或I，或者Y为H且Z为Cl、Br、I、C.tbd.N--或SCN--，或者Y为芳基硒基且Z为Cl或Br；当n为零或1时，对氢解产物进行氧化反应；通过氧化对应化合物（VI）制备公式为（VI，n=2）的化合物的过程，其中n为零或1，并且在上述过程中使用的某些新型中间体。
• 6-Alpha-halopenicillanic acid 1,1-dioxides
  申请人：Pfizer Inc.

  公开号：US04420426A1

  公开（公告）日：1983-12-13

  A process for the preparation of penicillanic acid 1,1-dioxide and esters thereof readily hydrolyzable in vivo, which comprises oxidation of a 6-halopenicillanic acid, or an ester thereof readily hydrolyzable in vivo, to the corresponding 6-halopenicillanic acid 1,1-dioxide or ester thereof, followed by dehalogenation (e.g. by hydrogenolysis). Certain of the 6-halopenicillanic acid 1,1-dioxides and esters thereof readily hydrolyzable in vivo are novel intermediates. Penicillanic acid 1,1-dioxide, and esters thereof readily hydrolyzable in vivo are known compounds which are beta-lactamase inhibitors and which enhance the effectiveness of certain beta-lactam antibiotics (e.g. the penicillins) in the treatment of bacterial infections in mammals, particularly humans.

  一种制备在体内容易水解的青霉烷酸1,1-二氧化物及其酯的方法，包括将6-卤代青霉酸或在体内容易水解的其酯氧化为相应的6-卤代青霉酸1,1-二氧化物或其酯，然后进行去卤代反应（例如氢解）。其中一些在体内容易水解的6-卤代青霉酸1,1-二氧化物及其酯是新颖的中间体。青霉烷酸1,1-二氧化物及其在体内容易水解的酯是已知的化合物，它们是β-内酰胺酶抑制剂，可以增强特定β-内酰胺类抗生素（例如青霉素）在哺乳动物，尤其是人类的细菌感染治疗中的有效性。
• Process for preparing penicillanic acid 1,1-dioxide derivatives and certain intermediates useful therein
  申请人：PFIZER INC.

  公开号：EP0061315A1

  公开（公告）日：1982-09-29

  A process for the preparation of penicillanic acid 1,1-dioxide derivatives of the formula:- wherein X is Cl, Br, I or OSO2R1 where R1 is C1-C6 alkyl or C6H4R2 where R2 is H, Cl, Br, l, NO2, C1-C3 alkyl or C1-C3 alkoxy, by reducing a compound of the formula wherein X is as defined for formula (I), n is zero, 1 or 2; Y and Z are each Cl, Br or l, orY is H and Z is selected from Cl, Br, l, C≡N- (isocyano) and SCN- (isothiocyanato), or Y is SeC6H4R2 is as defined for formula (I), and Z is Cl or Br; with a specified reducing agent, followed by oxidation of a compound (VI) in which n is 0 or 1. The compounds (I) are intermediates for the production of valuable antibiotics. Also included are certain novel intermediates particularly those of the formula :- wherein X is Cl, Br, I or OSO2R1 where R' is C1-C6 alkyl or C6HaR2 where R2 is H, Cl, Br, l, NO2, C1-C3 alkyl or C1-C3 alkoxy; n is zero, 1 or2; Y1 is H and Z1 is C≡N- or SCN-, or Y1 is SeC6H4R2 and Z1 is Cl or Br, and R2 is H, Cl, Br, l, NO2, C1-C3 alkyl or C1-C3 alkoxy.

  一种制备青霉烷酸 1,1-二氧化物衍生物的工艺，其式为 式中 X 为 Cl、Br、I 或 OSO2R1（其中 R1 为 C1-C6 烷基）或 C6H4R2（其中 R2 为 H、Cl、Br、l、NO2、C1-C3 烷基或 C1-C3 烷氧基），通过还原式化合物 其中 X 如式 (I) 所定义，n 为 0、1 或 2；Y 和 Z 分别为 Cl、Br 或 l，或 Y 为 H，Z 选自 Cl、Br、l、C≡N-（异氰酸基）和 SCN-（异硫氰酸基），或 Y 是 SeC6H4R2，如式（I）所定义，Z 是 Cl 或 Br；用指定的还原剂，然后氧化其中 n 为 0 或 1 的化合物（VI）。 化合物（I）是生产有价值抗生素的中间体。此外，还包括某些新型中间体，特别是式如下的中间体 其中 X 是 Cl、Br、I 或 OSO2R1，其中 R' 是 C1-C6 烷基或 C6HaR2，其中 R2 是 H、Cl、Br、l、NO2、C1-C3 烷基或 C1-C3 烷氧基；n 是 0、1 或 2；Y1 是 H，Z1 是 C≡N- 或 SCN-，或 Y1 是 SeC6H4R2，Z1 是 Cl 或 Br，R2 是 H、Cl、Br、l、NO2、C1-C3 烷基或 C1-C3 烷氧基。
• Scope and Mechanism of Deprotection of Carboxylic Esters by Bis(tributyltin) Oxide
  作者：Claudio J. Salomon、Ernesto G. Mata、Oreste A. Mascaretti

  DOI：10.1021/jo00103a016

  日期：1994.12

  Methyl and ethyl esters of aliphatic and aromatic carboxylic acids as well as benzyl carboxylates, thiol esters and double esters such as (pivaloyloxy)methyl carboxylates have been successfully cleaved with bis(tributyltin) oxide to give the free carboxylic acids in good yields. The reaction is carried out in aprotic solvents under essentially neutral conditions and thus this method can serve as an ideal procedure for the cleavages of esters with other functional groups and/or protecting groups acid and/or base sensitive. We demonstrated that the reaction displays a high level of chemoselectivity between methyl and ethyl esters versus tert-butyl esters and gamma-lactones. Bis(tributyltin) oxide is also a highly efficient reagent for the cleavage of acetates of primary and secondary alcohols and phenols. The limitations we found in the use of this reagent include the lack. of cleavage of esters sterically hindered around the carboxyl carbon and the carbinol group (i.e., esters of tertiary alcohols) and in carboxylic esters that contain a fluoroalkyl substituent. A resonable mechanistic explanation is discussed to account for the reaction pathway of the acyloxygen cleavage of(-)-(1R)-menthyl acetate.